Related references
Note: Only part of the references are listed.Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
Sharana Mahomed et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Targeting Fc effector function in vaccine design
Simone I. Richardson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
L. Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques
Justin Pollara et al.
FRONTIERS IN IMMUNOLOGY (2021)
Coming together at the hinges: Therapeutic prospects of IgG3
Thach H. Chu et al.
MABS (2021)
VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA
Manxue Jia et al.
CELL HOST & MICROBE (2020)
Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies
Thach H. Chu et al.
PLOS PATHOGENS (2020)
FcγR Binding and ADCC Activity of Human IgG Allotypes
Steven W. de Taeye et al.
FRONTIERS IN IMMUNOLOGY (2020)
IgA Summons IgG to Take a Hit at HIV-1
Giuliana Magri et al.
CELL HOST & MICROBE (2020)
Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity
Charles D. Murin
FRONTIERS IN IMMUNOLOGY (2020)
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
Mangaiarkarasi Asokan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo
Pengfei Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV
Ali Danesh et al.
CURRENT OPINION IN HIV AND AIDS (2020)
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge
Kier Om et al.
PLOS PATHOGENS (2020)
Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape
Cathrine Scheepers et al.
CELL REPORTS (2020)
A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress
Seiji Saito et al.
PROTEIN SCIENCE (2019)
The Neonatal Fc Receptor (FcRn): A Misnomer?
Michal Pyzik et al.
FRONTIERS IN IMMUNOLOGY (2019)
Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
Dora Pinto et al.
CELL HOST & MICROBE (2019)
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk
Scott D. Neidich et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
Simone I. Richardson et al.
PLOS PATHOGENS (2019)
Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms
Kashyap R. Patel et al.
FRONTIERS IN IMMUNOLOGY (2019)
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
Nicole M. Piche-Nicholas et al.
MABS (2018)
Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges
Ann J. Hessell et al.
JOURNAL OF VIROLOGY (2018)
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies
Simone I. Richardson et al.
PLOS PATHOGENS (2018)
Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV
Margaret E. Ackerman et al.
NATURE MEDICINE (2018)
Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies
Matthew S. Parsons et al.
RETROVIROLOGY (2018)
Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement
Giuseppe Lofano et al.
SCIENCE IMMUNOLOGY (2018)
Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies
Hannah M. Cheeseman et al.
JOURNAL OF VIROLOGY (2017)
Diversification of IgG effector functions
Stylianos Bournazos et al.
INTERNATIONAL IMMUNOLOGY (2017)
Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir
Shariq Mujib et al.
JOURNAL OF VIROLOGY (2017)
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge
Boris Julg et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Immunoregulatory Roles of Antibody Glycosylation
Madeleine F. Jennewein et al.
TRENDS IN IMMUNOLOGY (2017)
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
Todd Bradley et al.
NATURE COMMUNICATIONS (2017)
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
Joshua A. Horwitz et al.
CELL (2017)
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency
Nicole A. Doria-Rose et al.
JOURNAL OF VIROLOGY (2016)
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
Stylianos Bournazos et al.
CELL (2016)
Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity
S. Giuntini et al.
CLINICAL AND VACCINE IMMUNOLOGY (2016)
Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies
Benjamin von Bredow et al.
JOURNAL OF VIROLOGY (2016)
Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies
M. Sips et al.
MUCOSAL IMMUNOLOGY (2016)
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
Rajeev Gautam et al.
NATURE (2016)
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo
Ching-Lan Lu et al.
SCIENCE (2016)
Elimination of HIV-1-infected cells by broadly neutralizing antibodies
Timothee Bruel et al.
NATURE COMMUNICATIONS (2016)
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C
Kshitij Wagh et al.
PLOS PATHOGENS (2016)
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses
Matthew Zirui Tay et al.
PLOS PATHOGENS (2016)
Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control
Margaret E. Ackerman et al.
PLOS PATHOGENS (2016)
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
Rena D. Astronomo et al.
EBIOMEDICINE (2016)
Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function
Michael O. Alberti et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2015)
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey et al.
NATURE (2015)
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Angela Schoch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Sampa Santra et al.
PLOS PATHOGENS (2015)
Investigating the Interaction between the Neonatal Fc Receptor and Monoclonal Antibody Variants by Hydrogen/Deuterium Exchange Mass Spectrometry
Pernille Foged Jensen et al.
MOLECULAR & CELLULAR PROTEOMICS (2015)
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Stylianos Bournazos et al.
CELL (2014)
Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
Ariel Halper-Stromberg et al.
CELL (2014)
Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Allan deCamp et al.
JOURNAL OF VIROLOGY (2014)
HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities
Justin Pollara et al.
JOURNAL OF VIROLOGY (2014)
Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques
C. Moog et al.
MUCOSAL IMMUNOLOGY (2014)
Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines
Amy W. Chung et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
Nicole L. Yates et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge
Katja Klein et al.
JOURNAL OF VIROLOGY (2013)
Enhanced Phagocytic Activity of HIV-Specific Antibodies Correlates with Natural Production of Immunoglobulins with Skewed Affinity for FcγR2a and FcγR2b
Margaret E. Ackerman et al.
JOURNAL OF VIROLOGY (2013)
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Tilman Schlothauer et al.
MABS (2013)
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
Rogier W. Sanders et al.
PLOS PATHOGENS (2013)
Properties of mouse and human IgG receptors and their contribution to disease models
Pierre Bruhns
BLOOD (2012)
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Jinghe Huang et al.
NATURE (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody
Daniela Tudor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo
Brian Moldt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences
Weirong Wang et al.
DRUG METABOLISM AND DISPOSITION (2011)
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Margaret E. Ackerman et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
A Panel of IgG1 b12 Variants with Selectively Diminished or Enhanced Affinity for Fcγ Receptors To Define the Role of Effector Functions in Protection against HIV
Brian Moldt et al.
JOURNAL OF VIROLOGY (2011)
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
Nigel M. Stapleton et al.
NATURE COMMUNICATIONS (2011)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
Ann J. Hessell et al.
NATURE MEDICINE (2009)
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J. Hessell et al.
NATURE (2007)
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
E. S. Gray et al.
JOURNAL OF VIROLOGY (2007)
Distribution and three-dimensional structure of AIDS virus envelope spikes
Ping Zhu et al.
NATURE (2006)
Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals
LA Cavacini et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2003)
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 the presence of natural-killer effector cells
DN Forthal et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
